Quantbot Technologies LP Arcus Biosciences, Inc. Transaction History

Quantbot Technologies LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$16.97 - $22.03 $5,091 - $6,609	300 New	300 $6,000
Q4 2021 Feb 11, 2022	SELL	$31.38 - $48.47 $62,760 - $96,940	-2,000 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$26.93 - $37.68 $53,860 - $75,360	2,000 New	2,000 $69,000
Q2 2021 Aug 12, 2021	SELL	$22.75 - $35.77 $5,391 - $8,477	-237 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$26.16 - $41.39 $6,199 - $9,809	237 New	237 $6,000
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $8,500 - $16,180	-500 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$17.14 - $25.47 $8,570 - $12,735	500 New	500 $8,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.